Prevalence and incidence of left ventricular systolic dysfunction and adverse outcomes in patients receiving de novo and replacement pacemaker therapy for bradycardia
Prospective data reveals heart failure rates in patients receiving pacemaker therapy, indicating a higher risk in those with left ventricular systolic dysfunction.
Key Points
To assess the prevalence and predictors of left ventricular systolic dysfunction and heart failure outcomes in patients undergoing pacemaker therapy.
Prospective data collection from 1024 patients
Comparison between de novo and replacement RVP cases
Logistic regression models to identify predictors of LVSD and HF outcomes
LVSD observed in 37% of patients
De novo patients had a higher prevalence of LVSD than replacement patients (20% vs 17%)
33% faced hospitalisation for heart failure or death over 30 months, with higher rates in replacement patients (25% vs 8%)